Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Practice Guidelines
    • Anesthesiology Guidelines
    • NICE Guideline on...

    NICE Guideline on diagnosis and management of Drug allergy

    Written by Dr. Kamal Kant Kohli Kohli Published On 2018-08-08T19:03:51+05:30  |  Updated On 8 Aug 2018 7:03 PM IST
    NICE Guideline on diagnosis and management of Drug allergy

    NICE has come out its Guidance on diagnosis and management of Drug allergy. According to the Guideline, drug allergy has been defined as any reaction caused by a drug with clinical features compatible with an immunological mechanism.


    The British Society for Allergy and Clinical Immunology (BSACI) defines drug allergy as an adverse drug reaction with an established immunological mechanism. All drugs have the potential to cause 'adverse drug reactions, but not all of these are allergic in nature. The guidelines suggest that while assessing a person presenting with possible drug allergy, take a history and undertake a clinical examination. Use the following boxes as a guide when deciding whether to suspect a drug allergy


    Signs and allergic patterns of suspected drug allergy with the timing of onset*






















    Box 1 Immediate, rapidly evolving reactions
    Anaphylaxis—a severe multi-system reaction characterised by:

    • erythema, urticaria or angioedema and

    • hypotension and/or bronchospasm


    Onset usually less than 1 hour after drug exposure (previous exposure not always confirmed)
    Urticaria or angioedema without systemic features
    Exacerbation of asthma (for example, with non-steroidal anti-inflammatory drugs [NSAIDs])


















    Box 2 Non-immediate reactions without systemic involvement
    Widespread red macules or papules (exanthema-like)Onset usually 6–10 days after first drug exposure or within 3 days of second exposure
    Fixed drug eruption (localised inflamed skin)



























    Box 3 Non-immediate reactions with systemic involvement
    Drug reaction with eosinophilia and systemic symptoms (DRESS) or drug hypersensitivity syndrome (DHS) characterized by:

    • widespread red macules, papules or erythroderma

    • fever

    • lymphadenopathy

    • liver dysfunction

    • eosinophilia


    Onset usually 2–6weeks after first drug exposure or within 3days of second exposure
    Toxic epidermal necrolysis or Stevens-Johnson syndrome characterized by:

    • painful rash and fever (often early signs)

    • mucosal or cutaneous erosions

    • vesicles, blistering or epidermal detachment

    • red purpuric macules or erythema multiforme


    Onset usually 7–14days after first drug exposure or within 3days of second exposure
    Acute generalized exanthematous pustulosis (AGEP) characterized by:

    • widespread pustules

    • fever

    • neutrophilia


    Onset usually 3–5 days after first drug exposure
    Common disorders caused, rarely, by drug allergy:

    • eczema

    • hepatitis

    • nephritis

    • photosensitivity

    • vasculitis


    Time of onset variable



    * Note that these boxes describe common and important presenting features of drug allergy but other presentations are also recognised




    • Be aware that the reaction is more likely to be caused by drug allergy if it occurred during or after use of the drug and:

      • the drug is known to cause that type of reaction or

      • the person has previously had a similar reaction to that drug or drug class



    • Be aware that the reaction is less likely to be caused by drug allergy if:

      • there is a possible non-drug cause for the person's symptoms (for example, they have had similar symptoms when not taking the drug) or

      • the person has gastrointestinal symptoms only




    Measuring serum tryptase after suspected anaphylaxis




    • After a suspected drug-related anaphylactic reaction, take 2 blood samples for mast cell tryptase in line with recommendations in Anaphylaxis .

    • Record the exact timing of both blood samples taken for mast cell tryptase:

      • in the person's medical records and

      • on the pathology request form



    • Ensure that tryptase sampling tubes are included in emergency anaphylaxis kits


    Measuring serum specific immunoglobulin E




    • Do not use blood testing for serum specific immunoglobulin E (IgE) to diagnose drug allergy in a non-specialist setting


    Documenting and sharing information with other healthcare professionals


    Recording drug allergy status




    • Document people's drug allergy status in their medical records using one of the following:

      • 'drug allergy'

      • 'none known'

      • 'unable to ascertain' (document it as soon as the information is available)



    • If drug allergy status has been documented, record all of the following at a minimum:

      • the drug name

      • the signs, symptoms and severity of the reaction (see Boxes 1–3, above)

      • the date when the reaction occurred







    Providing information and support to patients




    • Discuss the person's suspected drug allergy with them (and their family members or carers as appropriate) and provide structured written information. Record who provided the information and when

    • Ensure that the person (and their family members or carers as appropriate) is aware of the drugs or drug classes that they need to avoid, and advise them to check with a pharmacist before taking any over-the-counter preparations

    • Advise people (and their family members or carers as appropriate) to carry information they are given about their drug allergy at all times and to share this whenever they visit a healthcare professional or are prescribed, dispensed or are about to be administered a drug


    Non-specialist management and referral to specialist services



    General



    • If drug allergy is suspected:

      • consider stopping the drug suspected to have caused the allergic reaction and advising the person to avoid that drug in future

      • treat the symptoms of the acute reaction if needed; send people with severe reactions to hospital

      • document details of the suspected drug allergy in the person's medical records

      • provide the person with information (see section above)



    • Refer people to a specialist drug allergy service if they have had:

      • a suspected anaphylactic reaction or

      • a severe non-immediate cutaneous reaction (for example, drug reaction with eosinophilia and systemic symptoms [DRESS], Stevens–Johnson Syndrome, toxic epidermal necrolysis)




    Non-steroidal anti-inflammatory drugs (including selective cyclooxygenase 2 inhibitors)




    • Explain to people with a suspected allergy to a non-selective non-steroidal anti-inflammatory drug (NSAID) (and their family members or carers as appropriate) that in future they need to avoid all non-selective NSAIDs, including over-the-counter preparations

    • For people who have had a mild allergic reaction to a non-selective NSAID but need an anti-inflammatory:

      • discuss the benefits and risks of selective cyclooxygenase 2 (COX-2) inhibitors (including the low risk of drug allergy)

      • consider introducing a selective COX-2 inhibitor at the lowest starting dose with only a single dose on the first day



    • Do not offer a selective COX-2 inhibitor to people in a non-specialist setting if they have had a severe reaction, such as anaphylaxis, severe angioedema or an asthmatic reaction, to a non-selective NSAID

    • Refer people who need treatment with an NSAID to a specialist drug allergy service if they have had a suspected allergic reaction to an NSAID with symptoms such as anaphylaxis, severe angioedema or an asthmatic reaction

    • Be aware that people with asthma who also have nasal polyps are likely to have NSAID-sensitive asthma unless they are known to have tolerated NSAIDs in the last 12 months


    Beta-lactam antibiotics




    • Refer people with a suspected allergy to beta-lactam antibiotics to a specialist drug allergy service if they:

      • need treatment for a disease or condition that can only be treated by a beta-lactam antibiotic or

      • are likely to need beta-lactam antibiotics frequently in the future (for example, people with recurrent bacterial infections or immune deficiency)



    • Consider referring people to a specialist drug allergy service if they are not able to take beta-lactam antibiotics and at least 1 other class of antibiotic because of suspected allergy to these antibiotics


    Local anaesthetics




    • Refer people to a specialist drug allergy service if they need a procedure involving a local anaesthetic that they are unable to have because of suspected allergy to local anaesthetics


    General anaesthesia




    • Refer people to a specialist drug allergy service if they have had anaphylaxis or another suspected allergic reaction during or immediately after general anaesthesia.


    For further reference log on to:



    www.nice.org.uk/guidance/CG183.



    British Society for Allergy and Clinical ImmunologyBSACIDHSDRESSDrug allergydrug hypersensitivity syndromeDrug reaction with eosinophilia and systemic symptomsimmunological mechanismNICE guideline
    Source : With inputs from NICE

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Dr. Kamal Kant Kohli Kohli
    Dr. Kamal Kant Kohli Kohli
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok